NCT00002189CompletedPhase 2
Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals
Baker Norton Pharmaceuticals2 sites in 1 countryStarted: August 31, 2001Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Locations
- 2
Study Overview
Brief Summary
To determine response rate, median time to tumor progression, qualitative and quantitative toxicity and reversibility of toxicity in patients with advanced refractory AIDS-associated Kaposi's sarcoma (KS) administered a 3-hour infusion of paclitaxel every 14 days. To evaluate the clinical benefit of paclitaxel in this patient population by evaluating self-reported responses to the Symptom Distress Scale and by documenting and evaluating any changes in their lymphedema, pain and disfiguring facial lesions.
Detailed Description
Patients are treated with paclitaxel intravenously every 2 weeks up to 10 courses. Patients who achieve a complete response receive 2 additional courses those who achieve partial response or stabilization, continue therapy until progression.
Study Design
- Study Type
- Interventional
- Primary Purpose
- Treatment
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients must have:
- •Microscopically confirmed diagnosis of KS associated with HIV for which systematic therapy is medically indicated by the presence of at least one of the following:
- •A. >= 25 mucocutaneous (mouth or skin) lesions. B. Symptomatic visceral involvement. C. Symptomatic lymphedema (pain).
- •Minimum of 5 clearly measurably cutaneous lesions by physical exam or measurable disease by X-ray, CT or MRI.
- •Failed at least one systemic chemotherapy regimen.
Exclusion Criteria
- •Co-existing Condition:
- •Patients with the following conditions and symptoms are excluded:
- •Less than 2 weeks since major surgery.
- •Serious uncontrolled infection. NOTE:
- •Must be ruled out by thorough work-up in patients with unexplained fevers, night sweats, or involuntary weight loss of more than 10% normal weight.
- •Leukopenia.
- •Thrombocytopenia.
- •Patients with the following prior conditions are excluded:
- •History of angina or myocardial infarction within the past 6 months.
- •Second degree or third degree atrioventricular block without a pacemaker.
- •Congestive heart failure (poorly controlled).
- •History of prior malignancy except:
- •Completely excised in situ, carcinoma of the cervix or nonmelanomatous skin cancer.
- •Curatively treated other malignancy with no evidence of disease for at least 5 years.
- •Prior Medication:
- •Prior taxane therapy.
- •At least one systemic chemotherapy regimen that failed to maintain significant benefit. NOTE:
- •Intralesional chemotherapy regimens are not considered as prior chemotherapy.
- •At least 2 weeks since last dose of prior systemic chemotherapy.
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 2
Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine CarcinosarcomaUterine CarcinosarcomaNCT00687687Sanofi22
Completed
Phase 1
A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)Solid TumorsNSCLCNCT01100931National Cancer Institute (NCI)42
Completed
Phase 2
Weekly Paclitaxel Plus Carboplatin in Preoperative Treatment of Breast CancerBreast CancerNCT01203267Shanghai Jiao Tong University School of Medicine108
Completed
Phase 2
Taxol(Paclitaxel),UFT and Leucovorin in Patients With Advanced Gastric CancerGastric CancerNCT00154778National Taiwan University Hospital55
Active, not recruiting
Phase 1
Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous AngiosarcomaCutaneous AngiosarcomaNCT03921008Washington University School of Medicine20